Dorothée Selimoglu‐Buet

This study integrates clinical and T-cell immune profiling to identify early biomarkers of response to CD3xBCMA bispecific antibody therapy in multiple myeloma.

This study identifies a pro-inflammatory role of Granzyme K-producing bystander CD8+ T cells in AML, which promote IL-8 secretion and may exacerbate disease progression.

This study identifies granulocyte-derived resistin as a key factor in CMML that inhibits monocyte maturation and promotes immune suppression.

This study shows that combining DNA hypomethylating agents with H3K9me2 inhibitors reactivates immune pathways and eliminates malignant stem cells in CMML by targeting heterochromatin disorganization.

The paper identifies CXCL8 secreted by immature granulocytes as a factor inhibiting wildtype hematopoiesis in CMML, suggesting CXCL8 blockade could slow disease progression.